This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
1 Feb 2011

Alexion Announces $111M Acquisition of Taligen

Alexion Pharmaceuticals bought privately held biotechnology firm Taligen Therapeutics for $111 million, to expand its product portfolio.

Alexion Pharmaceuticals announced its acquisition of Taligen Therapeutics, a privately held development-stage biotechnology company. The $111 million acquisition broadens Alexion’s list of product candidates and expands Alexion’s capabilities in translational medicine by bringing in additional researchers.
 
Taligen has a number of preclinical compounds, including potential treatments for patients with ophthalmic diseases such as age-related macular degeneration (AMD), as well as other novel antibody and protein regulators of the complement inflammatory pathways.

Related News